Most online writing about MT-2 and PT-141 starts from outcomes. Research writing starts from receptors. The distinction matters, because these two molecules are best understood as pharmacological tools for interrogating the melanocortin system, a small family of G protein-coupled receptors with unusually broad biology. This overview covers what that system is, how the two compounds relate to each other structurally, and what characterization matters at the bench.
Cerberus Research Labs supplies compounds strictly for laboratory research use. Nothing here is dosing guidance, medical advice, or a therapeutic claim, and no compound discussed is offered for human or veterinary use.
The melanocortin system in one page
The system has three parts: ligands cleaved from a common precursor, receptors, and endogenous antagonists.
- Precursor and ligands. Pro-opiomelanocortin (POMC) is processed into several peptides, including adrenocorticotropic hormone (ACTH) and the alpha-, beta- and gamma-melanocyte-stimulating hormones (MSH). All share a conserved core sequence, His-Phe-Arg-Trp, that is central to receptor recognition.
- Five receptors. MC1R through MC5R are all G protein-coupled receptors that signal predominantly through Gs and cyclic AMP. MC1R is best known from pigmentation biology; MC2R is the ACTH receptor and depends on an accessory protein (MRAP) to reach the cell surface; MC3R and MC4R are prominent in the central nervous system and are studied in energy-balance research; MC5R is expressed in exocrine tissues and studied in that context.
- Endogenous antagonists. Unusually for a GPCR family, the melanocortin receptors have natural antagonists or inverse agonists: agouti-signaling protein (ASIP) and agouti-related protein (AgRP). The push and pull between agonist and antagonist tone is a defining feature of the system.
Where MT-2 fits
Melanotan II (MT-2) is a synthetic cyclic heptapeptide designed as a stabilized analog of alpha-MSH. Two modifications explain most of its research usefulness. First, the ring closure, formed by a lactam bridge between an aspartate and a lysine side chain, constrains the molecule into a conformation that presents the His-Phe-Arg-Trp pharmacophore to the receptor. Second, substitution of D-phenylalanine and norleucine for native residues reduces susceptibility to proteolysis, which makes it a far more stable ligand than the native hormone in experimental systems.
In receptor-pharmacology work MT-2 is characterized as a non-selective agonist across MC1R, MC3R, MC4R and MC5R. That breadth is the reason it appears across very different research areas: the same molecule engages receptors whose tissue distribution and downstream biology differ. It also means that any experimental result needs to be interpreted with receptor selectivity in mind, ideally with selective antagonists or knockout models as controls, rather than attributed to a single receptor by assumption.
A related but distinct compound, Melanotan I (afamelanotide), is a linear alpha-MSH analog and should not be conflated with MT-2 in the literature. The two differ in structure and in receptor profile.
Where PT-141 fits
PT-141 (bremelanotide) is structurally the closest relative of MT-2. It shares the same cyclic core and differs at the C-terminus, where MT-2 carries an amide and PT-141 carries a free acid. Pharmacologically it is also a melanocortin agonist, but it is generally described as showing a comparatively greater emphasis on MC4R than MT-2 does, which is why it is discussed in the context of central melanocortin signaling.
A caution on reading the literature: PT-141 has its own regulatory history as a pharmaceutical substance, and that history is separate from research-grade material supplied for laboratory use. Findings from clinical settings do not transfer to research compounds, and Cerberus Research Labs makes no representation connecting the two.
Why the pair is useful together
Because the two molecules are near-identical structurally but differ in receptor profile, comparing them is a classic structure-activity experiment. Differences in response between MT-2 and PT-141 in the same assay can help researchers reason about which receptor subtypes contribute to an observed signal. This is a design strategy, not a statement about relative effect sizes; no comparative numbers are asserted here.
Experimental considerations
- Read-outs. The standard cell-based read-out is cAMP accumulation in cells expressing a single defined receptor subtype. Heterologous expression systems allow clean subtype-by-subtype profiling.
- Selectivity controls. Because both compounds are multi-receptor agonists, include a subtype-selective antagonist or a receptor-null control wherever an experiment claims a specific receptor mechanism.
- Identity and purity. Cyclic peptides are easy to mischaracterize. Confirm identity by mass and purity by HPLC against the lot-specific certificate of analysis; see the COA library and the documentation hub.
- Handling. Lyophilized peptide should be handled and reconstituted with aseptic technique in a suitable solvent for the assay. The reconstitution calculator helps with concentration arithmetic for stock solutions.
Research use only. Not for human use. Not for veterinary use. Nothing on this page is medical advice, and no statement here should be read as a claim of safety, efficacy or suitability for any purpose outside laboratory research.
Where to go next
Browse the full research catalog, or see the product pages for MT-2 and PT-141. Researchers interested in adjacent neuropeptide signaling may also find kisspeptin relevant to their work.